1.04
price down icon5.45%   -0.06
after-market 시간 외 거래: 1.04
loading
전일 마감가:
$1.10
열려 있는:
$1.07
하루 거래량:
1.32M
Relative Volume:
0.55
시가총액:
$94.48M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-0.7647
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
-6.31%
1개월 성능:
-11.86%
6개월 성능:
-17.46%
1년 성능:
-19.38%
1일 변동 폭
Value
$1.02
$1.10
1주일 범위
Value
$1.02
$1.125
52주 변동 폭
Value
$0.772
$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
명칭
Sellas Life Sciences Group Inc
Name
전화
(646) 200-5278
Name
주소
7 TIMES SQUARE, NEW YORK, NY
Name
직원
15
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
SLS's Discussions on Twitter

SLS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.04 94.48M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-07-21 개시 Cantor Fitzgerald Overweight
2018-11-01 개시 Oppenheimer Outperform
2018-04-02 개시 H.C. Wainwright Buy
2018-03-19 업그레이드 Maxim Group Hold → Buy

Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스

pulisher
01:06 AM

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

01:06 AM
pulisher
Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 08, 2025

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World

Mar 08, 2025
pulisher
Feb 27, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 26, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register

Feb 26, 2025
pulisher
Feb 22, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Feb 22, 2025
pulisher
Feb 21, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq

Feb 20, 2025
pulisher
Feb 12, 2025

SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle

Feb 12, 2025
pulisher
Feb 10, 2025

SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025
pulisher
Feb 04, 2025

Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News

Feb 04, 2025
pulisher
Feb 04, 2025

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World

Feb 04, 2025
pulisher
Feb 03, 2025

You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News

Feb 03, 2025
pulisher
Jan 31, 2025

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register

Jan 30, 2025
pulisher
Jan 29, 2025

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

Jan 29, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan

Jan 28, 2025
pulisher
Jan 24, 2025

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha

Jan 23, 2025

Sellas Life Sciences Group Inc (SLS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):